Protein-free calf blood extract - Lee's PharmaceuticalAlternative Names: Eyprotor
Latest Information Update: 30 May 2012
At a glance
- Originator Lees Pharmaceutical Holdings
- Class Anti-inflammatories; Cicatrizants; Eye disorder therapies
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Marketed Corneal injuries
Most Recent Events
- 30 May 2012 Launched for Corneal injuries in China (Topical)
- 13 May 2008 Registered for Corneal injuries in China (Topical)
- 31 Jan 2005 Clinical trials in Corneal injuries in China (Topical)